Abstract Disease prioritization for inclusion into Thailand’s population-based screening benefit package Sitaporn Youngkong*, Patsri Srisuwan†, Tanunya Koopitakkajorn*, Pritaporn Kingkaew*, Lily Ingsrisawang‡, Det Kedcham§, Sripen Tantivess*, Kanitta Bundhamcharoen#, Yot Teerawattananon* *He

Abstract Population-based screening for nephrosis, nephritis and renal stone in Thailand Patsri Srisuwan*, Tanunya Koopitakkajorn†, Det Kedcham‡, Pritaporn Kingkaew†, Sitaporn Youngkong†, Sripen Tantivess†, and Yot Teerawattananon† *Outpatient and Family Medicine Department, Phramongkutklao Ho

Abstract Population-based screening for atrial fibrillation (AF) in Thailand Patsri Srisuwan*, Tanunya Koopitakkajorn**, Pritaporn Kingkaew**, Sitaporn Youngkong**, Sripen Tantivess*, and Yot Teerawattananon* *Outpatient and Family Medicine Department, Phramongkutklao Hospital, **Health Interv

Abstract Development of a population-based screening for anemia in Thailand Tanunya Koopitakkajorn*, Patsri Srisuwan†, Pritaporn Kingkaew*, Sitaporn Youngkong*, Napatcha Wongchaya‡, Supatcharin Suwannakerd‡, Sripen Tantivess*, and Yot Teerawattananon* *Health Intervention and Technology Assess

Abstract Cost-utility analysis of screening for hepatitis B viral infection in Thailand Narisa Tantai*, Pitsaphun Werayingyong**, Pattara Leelahavarong** and Yot Teerawattananon** *Pharmaceutical Department, Faculty of Medicine Siriraj Hospital, Mahidol University, **Health Intervention and Te

Abstract Recommendation of population-based screening guideline for asthma in Thailand Patsri Srisuwan*, Tanunya Koopitakkajorn**, Pritaporn Kingkaew**, Sitaporn Youngkong**, Sripen Tantivess**, and Yot Teerawattananon**      *Outpatient and Family Medicine Department, Phramongkutklao Hospit

Abstract Population-based Screening for Tuberculosis in Thailand Patsri Srisuwan*, Tanunya Koopitakkajorn**, Pritaporn Kingkaew**, Sitaporn Youngkong**, Sripen Tantivess*, Yot Teerawattananon* *Outpatient and Family Medicine Department, Phramongkutklao Hospital, **Health Intervention and Techn

Abstract Development of Thailand’s population-based screening package Patsri Srisuwan*, Tanunya Koopitakkajorn†, Pritaporn Kingkaew†, Sitaporn Youngkong†, Lily Ingsrisawang‡, Det Kedcham§, Sripen Tantivess†, and Yot Teerawattananon† *Outpatient and Family Medicine Department, Phramongkutklao H

conomic evaluations have been widely used to inform and guide policy-making process in healthcare resources allocation as a part of an evidence package. An intervention is considered cost-effective if an ICER is less than a cost-effectiveness threshold (CET), where a CET represents the acceptable pr

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m